NCT05704933 2026-04-06
Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Completed
Clinical Trials
24 trialsNCT03276832 2026-03-19
Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT05279027 2025-09-19
Zr89 + PET Companion Trial
Abramson Cancer Center at Penn Medicine
Phase EARLY_PHASE1 Completed
NCT02652455 2025-08-19
Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Completed
NCT04581382 2025-07-10
Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT03784625 2025-02-13
MELRIV-1
Centre Jean Perrin
Phase EARLY_PHASE1 Completed
NCT04752267 2024-05-24
18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases
University of Southern California
Phase EARLY_PHASE1 Completed
NCT02013492 2022-12-06
Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery
Ohio State University Comprehensive Cancer Center
Phase EARLY_PHASE1 Completed
NCT00962845 2022-09-07
Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery
Rutgers, The State University of New Jersey
Phase EARLY_PHASE1 Completed
NCT03655756 2022-08-08
pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma
TuHURA Biosciences, Inc.
Phase EARLY_PHASE1 Completed
NCT02320305 2020-01-14
MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT02316795 2019-09-24
Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma
Washington University School of Medicine
Phase EARLY_PHASE1 Completed
NCT01789827 2019-08-05
Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT01666353 2019-02-08
PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase EARLY_PHASE1 Completed
NCT01748747 2018-10-09
Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT01568996 2018-01-09
Pilot Study Evaluating Sulforaphane in Atypical Nevi-Precursor Lesions
University of Pittsburgh
Phase EARLY_PHASE1 Completed
NCT00972933 2017-12-07
Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma
University of Pittsburgh
Phase EARLY_PHASE1 Completed
NCT01209676 2016-11-15
IMCgp100 in Advanced Unresectable Melanoma
University of Pennsylvania
Phase EARLY_PHASE1 Completed
NCT01425749 2016-04-04
Mel55
University of Virginia
Phase EARLY_PHASE1 Completed
NCT00276835 2015-04-10
Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer
Northwestern University
Phase EARLY_PHASE1 Completed
NCT00470379 2014-10-31
Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT00436410 2012-05-02
Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase EARLY_PHASE1 Completed
NCT00580060 2011-06-10
Injection Of AJCC Stage IIB, IIC, III And IV Melanoma Patients With A Multi-Epitope Peptide Vaccine Using GM-CSF DNA As An Adjuvant: A Pilot Trial To Assess Safety And Immunity
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Completed
NCT00743353 2009-02-02
K5
Siemens Molecular Imaging
Phase EARLY_PHASE1 Completed